BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors. 2017

Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China.

Two novel series of 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives bearing 1H-imidazole-4-carboxamido or (E)-3-hydrosulfonylacrylamido motifs (16-31 and 32-42) were designed, synthesized and evaluated for their in vitro cytotoxic activity. Most of the compounds exhibited moderate to excellent potency against tested three cell lines, and fifteen compounds were further examined for their inhibitory activity against c-Met kinase. The most promising compound 16 (c-Met kinase [IC50]=1.1nM) demonstrated high selectivity and remarkable cytotoxicity against HT-29, MKN-45 and A549 cells with IC50 values of 0.08, 0.22 and 0.07μM, which were 3.1-, 1.4- and 2.1-fold more active than Foretinib. The preliminary structure-activity relationships as well as molecular docking disclosed that 1H-imidazole-4-carboxamido as a linker was of great importance for the antitumor activity.

UI MeSH Term Description Entries
D011804 Quinolines
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking

Related Publications

Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
August 2015, Bioorganic & medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors.
May 2020, European journal of medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Synthesis and biological evaluation of 4-(2-fluorophenoxy)-3,3'-bipyridine derivatives as potential c-met inhibitors.
September 2016, European journal of medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design and optimization of novel 4-(2-fluorophenoxy)quinoline derivatives bearing a hydrazone moiety as c-Met kinase inhibitors.
November 2014, European journal of medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
November 2014, Bioorganic & medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design, synthesis, and biological evaluation of 4-(2-fluorophenoxy)-7-methoxyquinazoline derivatives as dual EGFR/c-Met inhibitors for the treatment of NSCLC.
January 2024, European journal of medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
May 2020, European journal of medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
June 2013, Bioorganic & medicinal chemistry,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design, synthesis and biological evaluation of quinoline amide derivatives as novel VEGFR-2 inhibitors.
November 2010, Bioorganic & medicinal chemistry letters,
Xiaoqiang Wang, and Nan Jiang, and Sijia Zhao, and Shuancheng Xi, and Jiao Wang, and Tongfei Jing, and Wenyu Zhang, and Ming Guo, and Ping Gong, and Xin Zhai
Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
June 2015, European journal of medicinal chemistry,
Copied contents to your clipboard!